Both previously published analyses investigating 4-week treatment protocols reported comparable results with the appearance of only two grad III leukocytopenias and one grade III anaemia in a total of 45 mCPRC patients after three treatment cycles [8] and only two grade III leucopenias and one grade III thrombocytopenia in a total of 62 mCRPC patients receiving up to seven cycles of 177Lu-labeled PSMA-RLT [9]. This evidence concerns the gene FOLH1 and anemia (phenotype).